Lexeo Therapeutics, Inc. develops gene therapies intended to treat genetic forms of cardiovascular disease. Its clinical programs include LX2006 for Friedreich ataxia cardiomyopathy and additional candidates addressing arrhythmogenic cardiomyopathy and hypertrophic cardiomyopathy through the delivery of functional genes using AAV vectors. The company focuses on cardiac-targeted genetic medicines for conditions with high unmet medical need.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -32.7 | — |
| Q2 2025 | 0 | — | -26.1 | — |
| Q3 2025 | 0 | — | -20.3 | — |
| Q4 2025 | 0 | — | -20.9 | — |
| Q1 2026 | 0 | — | -20.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Republic Digital Acquisition Company (RDAG), Wen Acquisition Corp. (WENN), Monro, Inc. (MNRO), Suja Life, Inc. (SUJA), Enanta Pharmaceuticals, Inc. (ENTA), Office Properties Income Trust (OPI)